We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock
CTIC

Delisted

CTIC was delisted on the 23rd of June, 2023.

Back to rankings

58 hedge funds and large institutions have $29.7M invested in CTI BioPharma Corp. (DE) Common Stock in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more capital invested

Capital invested by funds: $26.7M → $29.7M (+$3.08M)

5% less funds holding

Funds holding: 61 → 58 (-3)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

33% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 18

Holders
58
Holders Change
-3
Holders Change %
-4.92%
% of All Funds
1.45%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
8
Increased
12
Reduced
18
Closed
9
Calls
$33K
Puts
–
Net Calls
+$33K
Net Calls Change
+$28K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$1.09M
2
TA
Tiedemann Advisors
New York
+$139K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$94.9K
4
CG
Caprock Group
Idaho
+$62.2K
5
Marshall Wace
Marshall Wace
United Kingdom
+$62.2K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.6M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$248K
3
Deutsche Bank
Deutsche Bank
Germany
-$209K
4
Goldman Sachs
Goldman Sachs
New York
-$98.5K
5
Millennium Management
Millennium Management
New York
-$97.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$18.1M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$3.06M +$94.9K +22,883 +3%
UCFA
3
United Capital Financial Advisors
Texas
$2.16M – – –
BIT
4
BlackRock Institutional Trust
California
$1.41M – – –
SCM
5
Stonepine Capital Management
Oregon
$1.07M +$1.09M +261,714 New
Renaissance Technologies
6
Renaissance Technologies
New York
$709K -$93.9K -22,636 -12%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$472K +$15.3K +3,696 +3%
Goldman Sachs
8
Goldman Sachs
New York
$464K -$98.5K -23,743 -17%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$384K -$1.6M -384,763 -80%
William Blair & Company
10
William Blair & Company
Illinois
$209K – – –
Millennium Management
11
Millennium Management
New York
$184K -$97.8K -23,580 -34%
Northern Trust
12
Northern Trust
Illinois
$153K +$1.08K +260 +0.7%
CA
13
Commerzbank Aktiengesellschaft
Germany
$145K -$9.57K -2,306 -6%
TA
14
Tiedemann Advisors
New York
$136K +$139K +33,431 New
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$131K -$248K -59,681 -65%
WT
16
Washington Trust
Rhode Island
$128K -$40.1K -9,662 -24%
California Public Employees Retirement System
17
California Public Employees Retirement System
California
$120K -$6.26K -1,510 -5%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$88K -$5.83K -1,406 -6%
CG
19
Caprock Group
Idaho
$61K +$62.2K +15,000 New
Marshall Wace
20
Marshall Wace
United Kingdom
$60K +$62.2K +15,000 New
PAM
21
Panagora Asset Management
Massachusetts
$51K – – –
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$48K +$49K +11,818 New
State Street
23
State Street
Massachusetts
$45K – – –
VKH
24
Virtu KCG Holdings
New York
$44K +$32.4K +7,809 +261%
UBS Group
25
UBS Group
Switzerland
$35K -$2.21K -532 -6%
1
2 3

CTIC Hedge Fund Activity: Q4 2016 in Review

58 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q4 2016, worth a combined $29.7M — up 12% from $26.7M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of CTIC and 8 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 12 added.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $1.09M. The largest seller was Fidelity Investments, cutting an estimated $1.6M.

  • 58 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q4 2016, down from 61 in Q3 2016.
  • Funds reported $29.7M of CTI BioPharma Corp. (DE) Common Stock stock for Q4 2016, up 12% quarter-over-quarter.
  • 8 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q4 2016 and 9 closed out, a net change of -1 holder.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q4 2016 was Stonepine Capital Management, an estimated $1.09M added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q4 2016 was Fidelity Investments, an estimated $1.6M sold.

Based on aggregated 13F filings for Q4 2016.